TGFB1 and systemic sclerosis: Conversely, in SSc patients treated with the TGFβ inhibitor fresolimumab, reductions in skin gene expression of COMP but not the macrophage marker CD163 suggest that TGFβ inhibition affected fibroblast but not macrophage biology in the skin (79).